A study published in Nature Communications reports an association between receipt of the recombinant zoster vaccine (RZV) and reduced risk of developing dementia. Researchers analyzed population data and found statistical links consistent with lower dementia incidence among vaccinated cohorts after adjusting for confounders. Authors caution observational limits and note that the mechanism could relate to vaccine‑induced modulation of neuroinflammation or reduced varicella‑zoster reactivation. The finding adds to a growing dataset exploring non‑specific long‑term benefits of adult vaccines and will likely prompt prospective investigations to probe causality and biological pathways.